Oncogene-Induced Senescence Limits the Progression of Pancreatic Neoplasia through Production of Activin A.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
15 08 2020
Historique:
received: 19 12 2019
revised: 08 04 2020
accepted: 12 06 2020
pubmed: 20 6 2020
medline: 29 12 2020
entrez: 20 6 2020
Statut: ppublish

Résumé

Pancreatic ductal adenocarcinoma (PDAC) is a deadly and aggressive cancer. Understanding mechanisms that drive preneoplastic pancreatic lesions is necessary to improve early diagnostic and therapeutic strategies. Mutations and inactivation of activin-like kinase (ALK4) have been demonstrated to favor PDAC onset. Surprisingly, little is known regarding the ligands that drive ALK4 signaling in pancreatic cancer or how this signaling pathway limits the initiation of neoplastic lesions. In this study, data mining and histologic analyses performed on human and mouse tumor tissues revealed that activin A is the major ALK4 ligand that drives PDAC initiation. Activin A, which is absent in normal acinar cells, was strongly induced during acinar-to-ductal metaplasia (ADM), which was promoted by pancreatitis or the activation of Kras

Identifiants

pubmed: 32554750
pii: 0008-5472.CAN-19-3763
doi: 10.1158/0008-5472.CAN-19-3763
doi:

Substances chimiques

activin A 0
Activins 104625-48-1
Activin Receptors, Type I EC 2.7.11.30
Activin Receptors, Type II EC 2.7.11.30
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3359-3371

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Yajie Zhao (Y)

Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard University, Lyon, France.
Department of Geriatrics, Ruijin Hospital, School of Medicine, Shanghai Jia Tong University, Shanghai, China.

Zhichong Wu (Z)

Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard University, Lyon, France.

Marie Chanal (M)

Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard University, Lyon, France.

Fabienne Guillaumond (F)

Centre de Recherche en Cancérologie de Marseille, Unité 1068, Institut National de la Santé et de la Recherche Médicale, Marseille, France.
Institut Paoli-Calmettes, Marseille, France.
Unité Mixte de Recherche (UMR 7258), Centre national de la Recherche Scientifique, Marseille, France.
Université Aix-Marseille, Marseille, France.

Delphine Goehrig (D)

Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard University, Lyon, France.

Sophie Bachy (S)

Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard University, Lyon, France.

Moitza Principe (M)

Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard University, Lyon, France.

Audrey Ziverec (A)

Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard University, Lyon, France.

Jean-Michel Flaman (JM)

Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard University, Lyon, France.

Guillaume Collin (G)

Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard University, Lyon, France.

Richard Tomasini (R)

Centre de Recherche en Cancérologie de Marseille, Unité 1068, Institut National de la Santé et de la Recherche Médicale, Marseille, France.
Institut Paoli-Calmettes, Marseille, France.
Unité Mixte de Recherche (UMR 7258), Centre national de la Recherche Scientifique, Marseille, France.
Université Aix-Marseille, Marseille, France.

Arja Pasternack (A)

Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Olli Ritvos (O)

Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Sophie Vasseur (S)

Centre de Recherche en Cancérologie de Marseille, Unité 1068, Institut National de la Santé et de la Recherche Médicale, Marseille, France.
Institut Paoli-Calmettes, Marseille, France.
Unité Mixte de Recherche (UMR 7258), Centre national de la Recherche Scientifique, Marseille, France.
Université Aix-Marseille, Marseille, France.

David Bernard (D)

Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard University, Lyon, France.

Ana Hennino (A)

Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard University, Lyon, France.

Philippe Bertolino (P)

Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard University, Lyon, France. Philippe.Bertolino@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH